Innealta Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Innealta Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17	Closed	-$733	–	191
2024 Q2	$733	Buy	+17	New	+$614	﹤0.01%	1381

Other funds holding AGIO

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Innealta Capital's AGIO Position: Q3 2024 in Review

Innealta Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2024, closing a stake of 17 shares — an estimated $733 sold.

Innealta Capital first reported a position in AGIO in Q2 2024 and held it in 1 quarter. The position peaked at $733 in Q2 2024. 207 funds tracked by Wall St. Rank hold AGIO as of Q3 2024.

Innealta Capital reported no remaining Agios Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 17 Agios Pharmaceuticals shares in Q3 2024, an estimated $733.
Innealta Capital first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's Agios Pharmaceuticals position peaked at $733 in Q2 2024.
207 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.